Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Neovasc Inc. NVCN

Neovasc Inc is a specialty medical device company. It develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products the Neovasc Reducer (Reducer), for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and the Tiara, for the transcatheter... see more

Bullboard (NDAQ:NVCN)

View:
Comment by Monty2469on Mar 07, 2022 3:14pm

RE:Class action

you may have likely seen this since... https://neovasc.com/newsreleases/neovasc-announces-complete-dismissal-of-securities-class-action-complaint-with-prejudice/
Post by Betteryear2on Feb 04, 2022 9:09am

Neovasc Reducer™ Demonstrates Cost Savings

VANCOUVER and MINNEAPOLIS, Feb. 04, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc, Inc. (Neovasc or the Company) (NASDAQ, TSX: NVCN) today announced the publication of ...more  
Post by ENEMENEMYNEMOon Aug 30, 2021 9:15pm

Class action

Anyone know of any updates on the proposed class action against Neovasc for the shoddy FDA application?
Post by Betteryear2on Aug 17, 2021 9:19am

Submission of COSIRA-II Protocol Supplement to FDA

VANCOUVER and MINNEAPOLIS, Aug. 17, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (Nasdaq, TSX: NVCN) announced today that it has filed a ...more  
Post by Dalahlamaon Apr 16, 2021 12:35pm

Time to Buy!

Any price below a dollar is a steal for this stock. At current levels it's a no brainer!
Post by SmallCapPaulon Dec 29, 2020 10:58am

2020 Rearview Mirror - Worthwhile

CC is usually good for uncommon insight https://www.channelchek.com/news-channel/What_Do_Investors_Look_At_
Post by schoolofrockon Dec 11, 2020 11:34am

Virtual Road Show replay for those who missed it (Dec 8th)

"We hope you found the presentation and Q&A session informative and enjoyable. You can watch the replay, and find analyst Ahu Demir's research on Neovasc on Channelchek.com, at no cost ...more  
Post by schoolofrockon Dec 08, 2020 7:53am

Virtual Road Show with Neovasc President & CEO Fred Colen

Today @ 1pm (Eastern) - Virtual Road Show with Neovasc President & CEO, Fred Colen. Info at https://www.channelchek.com/news-channel/Channelchek_Virtual_Road_Show_Series
Comment by Havefun123on Oct 27, 2020 9:34pm

RE:RE:Such a weird stock

Seems like it's going to be very ugly tomorrow
Comment by mjh9413on Oct 27, 2020 3:44pm

RE:Such a weird stock

FDA meeting is/was scheduled for TODAY. last few days indicate it is not meant to end totally positively. eom
Post by Havefun123on Oct 24, 2020 3:45pm

Such a weird stock

For the last couple months, every time it started trending up, it went down even harder. Was there suppose to be some vote for FDA approval in Nov?
Post by SmallCapPaulon Aug 10, 2020 11:38am

Lots of Near-Term Catalysts

Reducer EU revenues declined due to COVID-19 https://www.channelchek.com/news-channel/Neovasc__NVCN___NVCN_CA____Q2_EPS_Preview__Lots_of_Near_Term_Catalysts
Post by bobus99on Jun 17, 2020 8:02pm

suspecious

i am suspecting this will go above 52 week high in less than 30 days
Post by mcdotcaon Jun 12, 2020 11:07am

180 Days from PMA Submission

I'm not sure how much Covid has or will impact the standard review process of the PMA application but I've read that the FDA requires 180 days. It was accepted for review Jan 15 so we should ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities